StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$143.37−1.09 (-0.75%)

Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%

Merck total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Merck's total debt was $53.91B at Jun 30, 2026. For fiscal 2025 it was $49.34B, up 32.9% from the year before. Over ten years it grew 6.4% a year on average. The highest annual figure on record is $49.34B in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$49.34B+32.9%
FY2024Dec 31, 2024$37.11B+5.9%
FY2023Dec 31, 2023$35.06B+14.2%
FY2022Dec 31, 2022$30.69B-7.3%
FY2021Dec 31, 2021$33.10B+4.1%
FY2020Dec 31, 2020$31.79B+20.7%
FY2019Dec 31, 2019$26.35B+4.9%
FY2018Dec 31, 2018$25.11B+2.9%
FY2017Dec 31, 2017$24.41B-1.7%
FY2016Dec 31, 2016$24.84B-5.9%
FY2015Dec 31, 2015$26.41B+23.4%
FY2014Dec 31, 2014$21.40B-14.6%
FY2013Dec 31, 2013$25.06B+21.8%
FY2012Dec 31, 2012$20.57B+17.4%
FY2011Dec 31, 2011$17.52B-2.1%
FY2010Dec 31, 2010$17.88B+2.3%
FY2009Dec 31, 2009$17.47B+180.0%
FY2008Dec 31, 2008$6.24B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$53.91B+52.3%
Q1 FY2026Mar 31, 2026$49.12B+41.0%
Q4 FY2025Dec 31, 2025$49.34B+32.9%
Q3 FY2025Sep 30, 2025$41.37B+8.5%
Q2 FY2025Jun 30, 2025$35.40B-6.3%
Q1 FY2025Mar 31, 2025$34.84B+1.8%
Q4 FY2024Dec 31, 2024$37.11B+5.9%
Q3 FY2024Sep 30, 2024$38.13B+9.4%
Q2 FY2024Jun 30, 2024$37.79B+2.4%
Q1 FY2024Mar 31, 2024$34.22B+11.3%
Q4 FY2023Dec 31, 2023$35.06B+14.2%
Q3 FY2023Sep 30, 2023$34.86B+14.6%
Q2 FY2023Jun 30, 2023$36.91B+16.6%
Q1 FY2023Mar 31, 2023$30.75B-3.3%
Q4 FY2022Dec 31, 2022$30.69B-7.3%
Q3 FY2022Sep 30, 2022$30.42B+15.0%
Q2 FY2022Jun 30, 2022$31.66B+19.4%
Q1 FY2022Mar 31, 2022$31.79B+1.7%
Q4 FY2021Dec 31, 2021$33.10B+4.1%
Q3 FY2021Sep 30, 2021$26.44B-8.0%
Q2 FY2021Jun 30, 2021$26.52B-14.1%
Q1 FY2021Mar 31, 2021$31.25B+11.6%
Q4 FY2020Dec 31, 2020$31.79B+20.7%
Q3 FY2020Sep 30, 2020$28.74B+10.2%
Q2 FY2020Jun 30, 2020$30.87B+16.1%
Q1 FY2020Mar 31, 2020$28.00B+8.1%
Q4 FY2019Dec 31, 2019$26.35B+4.9%
Q3 FY2019Sep 30, 2019$26.09B+10.6%
Q2 FY2019Jun 30, 2019$26.59B+13.9%
Q1 FY2019Mar 31, 2019$25.90B+9.9%
Q4 FY2018Dec 31, 2018$25.11B+2.9%
Q3 FY2018Sep 30, 2018$23.59B-12.6%
Q2 FY2018Jun 30, 2018$23.34B-6.2%
Q1 FY2018Mar 31, 2018$23.56B-17.3%
Q4 FY2017Dec 31, 2017$24.41B-1.7%
Q3 FY2017Sep 30, 2017$27.00B+7.4%
Q2 FY2017Jun 30, 2017$24.89B–
Q1 FY2017Mar 31, 2017$28.47B–
Q4 FY2016Dec 31, 2016$24.84B–
Q3 FY2016Sep 30, 2016$25.14B–

More Merck figures

See a number that looks wrong?